The Jiangsu manufacturing site has officially began operations.

The company was renamed Beijing Boehringer Ingelheim Vital Biotechnology Co., Ltd.

Beijing Meria-Vital Laboratory Animal Technology Co., Ltd. was established.

The eggs meet NIFDC standards for measles vaccine production.

The SPF chicken production facility was completed and trial production was initiated.

The project originated from the China-Australia international cooperation project commissioned by the Ministry of Foreign Trade and Economic Cooperation (MOFTEC).